Clinical trials: Double Incontinence
Overactive Bladder
Efficacy and Safety of Botulinum Toxin A for the Treatment of Refractory Overactive Bladder.
Overactive bladder induce urgency, urge incontinence, nocturia and pollakiuria. This condition is often resistant to anticholinergic drugs used as a first line treatment for this purpose.
- Trial name
- NCT00231491
- Testing
- Botulinum Toxin A (Botox )
- Where
- France
- Volunteers
- 160 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Stress Urinary Incontinence
A Phase 2, Randomized, Placebo-controlled, Double-blind Study of EG017 in Female Patients With Stress Urinary Incontinence
The purpose of this study is to determine whether EG017 is safe and effective in the treatment of stress urinary incontinence in postmenopausal women.
- Trial name
- NCT05674045
- Testing
- EG017 3mg, EG017 6mg
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Urinary Incontinence, Urge, Fecal Incontinence
Bladder Antimuscarinic Medication and Accidental Bowel Leakage
This observational research study will examine whether a medication known as darifenacin (Enablex ®) used for urgency urinary incontinence (UUI) also helps to improve fecal incontinence symptoms.
- Trial name
- BAMA (NCT03543566)
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Alabama at Birmingham
Urinary Incontinence (UI), Prostatectomy
Transcutaneous Tibial Nerve Stimulation for Urinary Incontinence After Radical Prostatectomy
Urinary incontinence (UI) after radical prostatectomy (RP) is a common postoperative complication that significantly affects quality of life.
- Trial name
- NCT07742176
- Testing
- Active Transcutaneous Tibial Nerve Stimulation (TTNS), Pelvic Floor Muscle Training (PFMT)
- Where
- Turkey (Türkiye)
- Volunteers
- 104 people
- Sponsor
- Pamukkale University
Stress Incontinence
Does Treatment With Macrobid Reduce Urinary Tract Infections in Patients Receiving a Sub-Urethral Sling for Incontinence
This project will determine whether post-operative prophylaxis with macrobid will decrease the incidence of postoperative urinary tract infection in women receiving sub-urethral slings for the treatment of urinary incontinence.
- Trial name
- NCT00734968
- Testing
- Nitrofurantoin
- Where
- United States
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
Overactive Bladder, Urinary Incontinence
ELB245 for 12 Weeks Versus 4mg Tolterodine in Patients With Incontinent Overactive Bladder (OAB)
This study is designed to determine the efficacy of escalating doses of ELB245 versus placebo , when administered to patients with OAB and to compare the efficacy of escalating doses of ELB245 versus the standard treatment…
- Trial name
- NCT00439192
- Testing
- ELB245, Tolterodine
- Where
- 31 sites in Germany, Poland and 1 more
- Volunteers
- 275 people
- Sponsor
- elbion AG
Stress Urinary Incontinence
Efficacy of Magnetic Stimulation for Stress Urinary Incontinence
The aim of the study is to investigate the effects of QRS®-1010 PelviCenter in female patients with stress urinary incontinence.
- Trial name
- NCT01924728
- Testing
- Magnetic stimulation
- Where
- Malaysia
- Volunteers
- 120 people
- Sponsor
- QRS Asia Sdn Bhd
Overactive Bladder
A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)
This study is designed to evaluate the safety, tolerability, and efficacy of vibegron administered once daily in patients with OAB.
- Trial name
- Empowur (NCT03492281)
- Testing
- vibegron, Tolterodine Tartrate ER
- Where
- 215 sites in United States, Canada and 4 more
- Volunteers
- 1,530 people
- Sponsor
- Urovant Sciences GmbH
Overactive Bladder
A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency
This study is designed to assess the efficacy of a flexible dose regimen of fesoterodine on micturition related nocturnal urgency episodes.
- Trial name
- NCT00911937
- Testing
- Fesoterodine
- Where
- 112 sites in United States
- Volunteers
- 963 people
- Sponsor
- Pfizer
Incontinence
Study of Escalating Doses of NRL001 Given in Slow-release Rectal Suppositories of Different Weights
Studies investigating single doses of different NRL001 formulations showed formulation-dependent differences in exposure, even though they had similar effects on mean anal resting pressure (MARP).
- Trial name
- NCT00850590
- Testing
- NRL001
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Norgine
Fecal Incontinence
Treatment of Fecal Incontinence After Obstetric Anal Sphincter Injuries
Fecal incontinence (FI), the involuntary loss of solid or liquid stool, is a stigmatising condition. It can have a distressing impact and restriction on quality of life.
- Trial name
- KISS (NCT01528995)
- Testing
- Medtronic Interstim II-3058, Anal bulking injection
- Where
- Norway
- Volunteers
- 68 people
- Sponsor
- University Hospital of North Norway
Stress Urinary Incontinence
Japanese Bridging Study of Autologous Muscle Derived Cells Compared to Placebo for Female Urinary Sphincter Repair(JPN1)
This is a confirmatory/bridging study to evaluate the efficacy and safety of Autologous Muscle Derived Cells for Urinary Sphincter Repair (AMDC-USR) compared with placebo in the treatment of stress urinary incontinence (SUI) in…
- Trial name
- JPN1 (NCT03997318)
- Testing
- AMDC-USR
- Sponsor
- Cook MyoSite
Overactive Bladder Syndrome
Safety and Efficacy of AV608 in Subjects With Idiopathic Detrusor Overactivity
The purpose of this study is to assess the effects of AV608, a neurokinin 1 (NK-1) antagonist, in subjects with Idiopathic Detrusor Overactivity.
- Trial name
- NCT00335660
- Testing
- AV608
- Where
- 13 sites in Netherlands, United Kingdom
- Volunteers
- 62 people
- Sponsor
- Avera Pharmaceuticals
Overactive Bladder
A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder
This study is designed to assess the efficacy and safety of a flexible dose regimen of fesoterodine on urgency urinary incontinence (UUI) episodes in vulnerable elderly subjects with overactive bladder (OAB).
- Trial name
- NCT00928070
- Testing
- Fesoterodine
- Where
- 125 sites in United States
- Volunteers
- 566 people
- Sponsor
- Pfizer
Faecal Incontinence
A Multi-centre, Phase II, Double-blind, Randomised, Placebo-controlled, Parallel Group, Dose-ranging Study in Patients With Faecal Incontinence; to Evaluate the Efficacy, Safety and Tolerability of Locally Applied NRL001 Over an 8 Week Treatment Period
The purpose of this study is to evaluate the safety, tolerability and efficacy of NRL001 in the treatment of faecal incontinence, compared against placebo
- Trial name
- NCT01656720
- Testing
- 1R, 2S-methoxamine hydrochloride
- Where
- 51 sites in Czechia, France and 7 more
- Volunteers
- 417 people
- Sponsor
- Norgine
Urinary Bladder Overactive, Overactive Bladder
A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder
The purpose of this study was to examine how well the combination of two medicines (solifenacin succinate and mirabegron) worked compared to each medicine alone in the treatment of bladder problems, and how safe they were for…
- Conditions
- Urinary Bladder Overactive, Overactive Bladder, Urgency Incontinence, Urinary Bladder Diseases\Urologic Diseases
- Trial name
- SYNERGY II (NCT02045862)
- Testing
- Solifenacin succinate, Mirabegron
- Where
- 251 sites in United States, Australia and 30 more
- Volunteers
- 1,829 people
- Sponsor
- Astellas Pharma Europe B.V.
Urinary Incontinence
A Placebo-Controlled Study of MK0634 in Patients With Overactive Bladder (0634-007)
Overactive bladder is very prevalent in postmenopausal women. The current study is designed to investigate whether a new drug may offer safe and effective treatment.
- Trial name
- NCT00231790
- Testing
- MK-0634 50 mg, MK-0634 125 mg
- Volunteers
- 848 people
- Sponsor
- Merck Sharp & Dohme LLC
Fecal Incontinence
Safety and Tolerability of a Single Intra-anal Dose of NRL001 in Healthy Volunteers
This study is conducted to explore the safety and tolerability and plasma pharmacokinetics of NRL001 after single intra-anal dose of 1mL cream at increasing concentrations.
- Trial name
- NCT01406925
- Testing
- NRL001 cream
- Where
- Bulgaria
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Norgine
Urinary Bladder Overactive, Urinary Bladder Diseases\Urologic Diseases
This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder
The purpose of this study was to examine how well two medicines (solifenacin succinate and mirabegron) combined work compared to each medicine alone in the treatment of bladder problems.
- Conditions
- Urinary Bladder Overactive, Urinary Bladder Diseases\Urologic Diseases, Overactive Bladder, Urgency Incontinence
- Trial name
- SYNERGY (NCT01972841)
- Testing
- Solifenacin succinate, Mirabegron
- Where
- 435 sites in United States, Argentina and 40 more
- Volunteers
- 3,527 people
- Sponsor
- Astellas Pharma Europe B.V.
Fecal Incontinence
Safety, Tolerability, Pharmacodynamic and Pharmacokinetics of 7.5, 10, 12.5 or 15 mg NRL001 in a 2 g Suppository for 14 Days
Healthy subjects will receive NRL001 or placebo once daily for 14 days. The four treatment groups, shown below, will each consist of 12 subjects: Group 1; Nine subjects will receive a dose of 7.5 mg NRL001 in a 2 g suppository…
- Trial name
- NCT01099670
- Testing
- NRL001
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Norgine